This activity is jointly provided by Purdue University and MCM Education.
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
An early and accurate diagnosis of interstitial lung disease (ILD) and its specific type is vital to directing therapy and monitoring disease course and therapeutic response, but these conditions are often mischaracterized and a correct diagnosis is very often delayed. Clinicians must be aware of the signs and symptoms that should raise suspicion of ILD. A comprehensive evaluation may improve the speed and accuracy of identification and classification of ILD. Treatment of ILD is also a challenge for clinicians, but recent advances hold promise for improved care and patient outcomes. This activity will examine recent advances in ILD diagnosis and treatment.
This activity is intended for pulmonologists, internal medicine specialists, primary care clinicians, radiologists, and other clinicians who encounter ILD.
Upon completion of this educational activity, the participant should be able to:
Discuss advances in ILD diagnosis and assessment
Review evidence-based treatment strategies for ILD
Discuss the optimal management of common comorbidities associated with ILD
Conflict Of Interest Disclosure Policy
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
David J. Lederer, MD, MS Associate Professor of Medicine Co-Director, Interstitial Lung Disease Program Columbia University Medical Center New York, NY
Dr. Lederer has disclosed the following: Grants/Research Support: Boehringer Ingelheim, Global Blood Therapeutics, Fibrogen Consultant: Roche, Patara, Immuneworks Advisory Board Membership: Global Blood Therapeutics, Fibrogen, Sanofi Genzyme, Philips Respironics Editorial Board Involvement: American Thoracic Society
Kevin R. Flaherty, MD, MS Professor of Medicine Director, University of Michigan Interstitial Lung Disease Program Chair, Pulmonary Fibrosis Foundation Clinical Care Network/Registry Steering Committee Ann Arbor, MI
Dr. Flaherty has disclosed the following: Grants/Research Support: Boehringer Ingelheim, Roche/Genentech Consultant: Boehringer Ingelheim, Roche/Genentech, Veractye, Fibrogen
Sonye K. Danoff, MD, PhD Associate Professor of Medicine Co-Director, Johns Hopkins ILD/IPF Program Associate Director, Johns Hopkins Myositis Center Baltimore, MD
Dr. Danoff has disclosed the following: Grants/Research Support: Genentech/Roche Advisory Board Membership: Boehringer Ingelheim, Global Blood Therapeutics
Accredited Provider Disclosure
All faculty and staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, reviewers, Purdue and MCM Education staff have nothing to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Purdue University, or Boehringer Ingelheim. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.